Linaclotide: A Novel Approach to the Treatment of Irritable Bowel Syndrome;Linaclotido: Un Nuevo Enfoque Para el Tratamiento del Síndrome del Colon Irritable

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages 1535-1543

  Wensel, Terri M ^a   Luthin, David R ^a  

^a SAMFORD UNIVERSITY   (United States)

Author keywords

Guanylate cyclase C agonist; Irritable bowel; Linaclotide; MD 1100

Indexed keywords

LINACLOTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HUMAN; IN VITRO STUDY; IRRITABLE COLON; MEDICAL LITERATURE; MEDLINE; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TOXICOLOGY; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83155182931     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q428     Document Type: Article

References (28)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:s1-s35.
2. Powell PH, Fleming VH. Diarrhea, constipation, and irritable bowel syndrome. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. 2011, New York, NY: McGraw Hill, 635-6.
3. Product information. Zelnorm (tegaserod). East Hanover, NJ: Novartis Pharmaceuticals, July 2006.
4. FDA announces discontinued marketing of GI drug, Zelnorm, for safety reasons. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm (accessed 2011 Jul 3).
5. FDA permits restricted use of Zelnorm for qualifying patients. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108956.htm (accessed 2011 Jul 3).
6. Zelnorm (tegaserod maleate) information. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm (accessed 2011 Jul 3).
7. Product information. Amitiza (lubiprostone). Bethesda, MD: Sucampo Pharma Americas, Inc., February 2011.
8. Johnston JM, Lavins BJ, MacDougall JE, et al. Time to onset of linaclotide effect on the bowel habits in patients with chronic constipation: results from a phase 2B study (abstract T1273). Gastroenterology 2009;136:A-537.
9. Lembo AJ, Johnston JM, MacDougall JE, et al. Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: data from a large 4-week, randomized, double-blind, placebo-controlled study (abstract). Gastroenterology 2008;135:295.
10. Lembo A, Schneier H, Lavins BJ, et al. Efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials (abstract 286). Gastroenterology 2010;138:s53-s54.
11. Johnston JM, Schneier H, Lavins BJ, et al. Results from the randomized withdrawal period of a phase 3 clinical trial of linaclotide in chronic constipation (abstract T1817). Gastroenterology 2010;138:s585.
12. Gastrointestinal program. Ironwood Pharmaceuticals. http://www.ironwoodpharma.com/gastrointestinal.php (accessed 2011 Jul 5).
13. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130:71-82.
14. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010;38:813-7.
15. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35.
16. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-5.
17. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84.
18. Kessler MM, Busby RW, Wakefield JD, et al. Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation (abstract 292). Drug Metab Rev 2008;40(suppl 3):213-4.
19. Kurtz C, Fitch D, Busby RW, Fretzen A, Ceis GS, Currie MG. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects (abstract 132). Gastroenterology 2006;130:A26.
20. Currie MG, Kurtz C, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects (abstract 894). Am J Gastroenterol 2005;100: s328.
21. Johnston J, MacDougall J, Lavins B, et al. Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: results from a large twelve-week, randomized, double-blind, placebo-controlled study (abstract 1179). Am J Gastroenterol 2008;103(S1):s460-1.
22. Johnston JM, Kurtz CB, MacDougal JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86.
23. Lembo AJ, Johnston JM, Lavins BJ, et al. Effect of linaclotide on IBS-C symptoms in the first week of treatment: results from a phase 2B study (abstract 157). Gastroenterology 2009;136:A-30-A-31.
24. Johnston JM, MacDougall JE, Lavins BJ, et al. Global endpoints in IBS clinical trials: results from a phase 2B study of linaclotide (abstract 236). Gastroenterology 2009;136:A-45-A-46.
25. Rao S, Lembo A, Shiff SJ, Shi K, Johnston JM, Schneier H. Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period (abstract 845). Gastroenterology 2011;140:s-138.
26. Chey WD, Lembo A, MacDougall JE, Lavins BJ, Schneier H, Johnston JM. Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, doubleblind, placebo-controlled phase 3 trial (abstract 837). Gastroenterology 2011;140:s-135.
27. Carson R, Tourkodimitris S, Lewis BE, Johnston JM. Effect of linaclotide on quality of life in adults with irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials (abstract 223). Gastroenterology 2011;140:s-51.
28. Guidance for industry. Irritable bowel syndrome clinical evaluation of products for treatment. Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf (accessed 2011 Aug 26).